» Articles » PMID: 17295177

Genomics and Signaling Pathways in Hepatocellular Carcinoma

Overview
Journal Semin Liver Dis
Publisher Thieme
Specialty Gastroenterology
Date 2007 Feb 14
PMID 17295177
Citations 239
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) is a leading cause of death among cirrhotic patients and has become a major health problem in developed countries. There is an elemental understanding of the genes and signaling pathways involved in the initiation and progression of this neoplasm. The current hypothesis of the HCC cell origin includes both somatic cells (hepatocytes) and stem cells/progenitor cells. Unlike that in other malignancies such as breast, brain, or hematopoietic cancers, the implication of cancer stem cells in HCC pathogenesis is not yet supported by consistent data. Analysis of somatic genetic alterations and gene expression profiles in HCC samples has provided relevant information on the genes involved in hepatocarcinogenesis, pinpointing a seminal molecular classification of the disease. Nonetheless, a comprehensive genomic analysis of HCC samples using high-resolution platforms in precisely annotated HCCs is clearly needed. Recent data have identified different signaling pathways in liver carcinogenesis (e.g., Wnt-betaCatenin, Hedgehog, tyrosine kinase receptor-related pathways), providing an important potential source of novel molecular targets for new therapies. This review summarizes the most relevant information regarding structural and functional alterations in HCC and describes some of the key signaling pathways implicated in hepatocarcinogenesis.

Citing Articles

Dual role of Nrf2 signaling in hepatocellular carcinoma: promoting development, immune evasion, and therapeutic challenges.

Gan L, Wang W, Jiang J, Tian K, Liu W, Cao Z Front Immunol. 2024; 15:1429836.

PMID: 39286246 PMC: 11402828. DOI: 10.3389/fimmu.2024.1429836.


Oncogenic Role of SATB2 In Vitro: Regulator of Pluripotency, Self-Renewal, and Epithelial-Mesenchymal Transition in Prostate Cancer.

Yu W, Srivastava R, Srivastava S, Ma Y, Shankar S, Srivastava R Cells. 2024; 13(11.

PMID: 38891096 PMC: 11171950. DOI: 10.3390/cells13110962.


Insights in Molecular Therapies for Hepatocellular Carcinoma.

Heumann P, Albert A, Gulow K, Tumen D, Muller M, Kandulski A Cancers (Basel). 2024; 16(10).

PMID: 38791911 PMC: 11120383. DOI: 10.3390/cancers16101831.


Prognosis and chemotherapy drug sensitivity in liver hepatocellular carcinoma through a disulfidptosis-related lncRNA signature.

Chen C, Wang C, Li Y, Jiang S, Yu N, Zhou G Sci Rep. 2024; 14(1):7157.

PMID: 38531953 PMC: 10965927. DOI: 10.1038/s41598-024-57954-7.


CREB3L4 promotes hepatocellular carcinoma progression and decreases sorafenib chemosensitivity by promoting RHEB-mTORC1 signaling pathway.

Jiang Z, Shi B, Zhang Y, Yu T, Cheng Y, Zhu J iScience. 2024; 27(2):108843.

PMID: 38303702 PMC: 10831937. DOI: 10.1016/j.isci.2024.108843.